EUVIMEDEUVIMED entdecken
Crossref

Integrated Analysis Reveals ZNF184 as a Novel Regulator of Stemness‐Associated Paclitaxel Resistance and Tumor Progression in Breast Cancer

Rong Gong, Yizhi Li, Xiaoya Wan, Shilong Jiang, Deyang Wang, Qi Fu, Anze Yang, Yidi Guan, Ruigang Zhao, Yan Cheng iD

Molecular Carcinogenesis · 2026

DOI: 10.1002/mc.70088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2026. Verfasst von Rong Gong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Paclitaxel, Drug Resistance, Neoplasm, Breast Neoplasms, Neoplastic Stem Cells. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Changsha Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy resistance is the primary cause of clinical treatment failure and unfavorable prognosis among breast cancer patients. Consequently, the exploration of novel molecular targets for chemotherapy resistance is warranted. Here, we demonstrated that Zinc Finger Protein 184 (ZNF184) facilitates chemoresistance in breast cancer. Through integrated bioinformatics and experimental validation, we identified that ZNF184 was highly expressed in paclitaxel‐resistant breast cancer cells. Knockdown of ZNF184 inhibited cell proliferation and re‐sensitized resistant cells to paclitaxel in vitro and in patients‐derived organoids (PDOs). Mechanistically, ZNF184 regulates the expression of stemness‐related genes CD44, OCT4, Nanog, SOX2, and ALDH1A1, thereby promoting the proliferation of breast cancer cells and subsequent paclitaxel resistance. Pan‐cancer analysis revealed the potential of ZNF184 as a prognostic and predictive biomarker for adverse clinical outcomes. Collectively, these findings reveal a previously unknown role of ZNF184 in breast cancer progression and paclitaxel resistance, providing new insights into ZNF184 as a potential therapeutic target for cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelDrug Resistance, NeoplasmBreast NeoplasmsNeoplastic Stem CellsBiomarkers, TumorHumansFemaleGene Expression Regulation, NeoplasticCell ProliferationPrognosisCell Line, TumorDisease ProgressionAnimalsAntineoplastic Agents, Phytogenic

Stichwörter der Autor:innen

ZNF184breast cancerpaclitaxel resistancestemness

Substanzen

PaclitaxelBiomarkers, TumorAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Hunan Provincial Engineering Research Center of Translational Medicine and Innovative Drug, Changsha, China.
  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
  • Zhuzhou Nanfang High School, Zhuzhou, China.
  • Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
  • Information and Network Center, Central South University, Changsha, China.

ORCID-Profile: Yan Cheng

Förderung

  • National Natural Science Foundation of China
  • Changsha Science and Technology Project

Zitieren

APA

Gong, R., Li, Y., Wan, X., Jiang, S., Wang, D., Fu, Q., Yang, A., Guan, Y., Zhao, R., & Cheng, Y. (2026). Integrated Analysis Reveals ZNF184 as a Novel Regulator of Stemness‐Associated Paclitaxel Resistance and Tumor Progression in Breast Cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70088

Vancouver

Gong R, Li Y, Wan X, Jiang S, Wang D, Fu Q, et al. Integrated Analysis Reveals ZNF184 as a Novel Regulator of Stemness‐Associated Paclitaxel Resistance and Tumor Progression in Breast Cancer. Molecular Carcinogenesis. 2026. doi:10.1002/mc.70088

BibTeX
@article{Gong2026,
  author = {Gong, Rong and Li, Yizhi and Wan, Xiaoya and Jiang, Shilong and Wang, Deyang and Fu, Qi and Yang, Anze and Guan, Yidi and Zhao, Ruigang and Cheng, Yan},
  title = {Integrated Analysis Reveals ZNF184 as a Novel Regulator of Stemness‐Associated Paclitaxel Resistance and Tumor Progression in Breast Cancer},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  doi = {10.1002/mc.70088}
}
Kostenlos starten →